IP Library Granted Patent US 11,510,995
Granted Patent B2
US 11,510,995 · App. 16/061,220 · Granted Nov 29, 2022

Nanosystems for controlled transport of active molecules for diagnostic, prognostic and therapeutic purposes

Inventors: Rosario Maria Sanchez Martin (Granada, ES); Salvatore Pernagallo (Granada, ES); Juan Diego Unciti Broceta (Cadiz, ES); Luciano Messina (Abano Terme, IT); Susanna Vaccaro (Abano Terme, IT); Laura Pilotto (Abano Terme, IT)
Assignees: FIDIA FARMACEUTICI S.P.A.; NANOGETIC S.L.
A61K47/6933A61K9/19A61K38/446A61K38/47A61K38/4886A61K47/6937A61K47/6939A61K9/0014A61K9/0019A61K9/0073A61K9/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,510,995
App. No.
16/061,220
Granted
Nov 29, 2022
Kind
B2
Abstract

Disclosed is a nanoparticle system consisting of a polymer support or substrate in the form of nanoparticles to which a hydrolase enzyme able to degrade hyaluronic acid and one or more biologically and/or pharmacologically active molecules are covalently bonded, its preparation process and its uses in the diagnostic, prognostic and therapeutic fields.

Claims (14)

1. A nanoparticle system comprising polystyrene nanoparticles, wherein the nanoparticles are 200 nm in size, and covalently bonded to a heterocarbon chain; a hyaluronidase; and one or more active molecules covalently bonded to said heterocarbon chain, wherein

the polystyrene nanoparticles covalently bonded to a heterocarbon chain are formed by reacting amino-functionalized polystyrene nanoparticles with N-Fmoc-N″-succinyl-4,7,10-trioxa-1,13-tridecanediamine to covalently bond primary amines on the polystyrene to functional groups on the heterocarbon chain;

the hyaluronidase is recombinant hyaluronidase rHyal_Sk; and

the one or more active molecules are an antibody and optionally a fluorophore, and wherein the recombinant hyaluronidase rHyal_Sk is bonded to the heterocarbon chain via diethyl squarate.

2. The nanoparticle system according to claim 1 wherein the covalent bonds between the functional groups of the heterocarbon chain and one or more active molecules are mediated by glutaraldehyde, maleimide, active esters, disulphide groups, squaric acid or derivatives thereof.

3. A pharmaceutical composition comprising the nanoparticle system of claim 1 in admixture with pharmaceutically acceptable excipients.

4. The pharmaceutical composition according to claim 3 in lyophilized form for reconstitution, or in aqueous suspension or gel form.

5. The pharmaceutical composition according to claim 3 for subcutaneous, intradermal, intrathecal, intramuscular, intraperitoneal, intravenous, intra-arterial, transdermal, transcutaneous, transmucosal or inhalatory administration.

6. A nanoparticle system comprising polystyrene nanoparticles, wherein the nanoparticles are 200 nm in size, and covalently bonded to a heterocarbon chain; a hyaluronidase; and one or more active molecules covalently bonded to said heterocarbon chain, wherein

the polystyrene nanoparticles covalently bonded to a heterocarbon chain are formed by reacting amino-functionalized polystyrene nanoparticles with N-Fmoc-N″-succinyl-4,7,10-trioxa-1,13-tridecanediamine to covalently bond primary amines on the polystyrene to functional groups on the heterocarbon chain;

the hyaluronidase is recombinant hyaluronidase rHyal_Sk; and

the one or more active molecules are an antibody and optionally a fluorophore, and wherein the recombinant hyaluronidase rHyal_Sk is bonded to the heterocarbon chain via diethyl squarate,

wherein the heterocarbon chain does not contain a free charge, and

wherein the one or more active molecules are bound to only one heterocarbon chain.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 12, 2018
From: SANCHEZ MARTIN, ROSARIO MARIA; PERNAGALLO, SALVATORE; UNCITI BROCETA, JUAN DIEGO; MESSINA, LUCIANO; VACCARO, SUSANNA; PILOTTO, LAURA
To: FIDIA FARMACEUTICI S.P.A.; NANOGETIC S.L.
Reel/Frame 046060/0655 →
Priority Claims (1)
IT 102015000085923 · Dec 21, 2015 · national
Continuity (1)
Related Publication 20180360990A1 · Dec 20, 2018
Cited By (6)
US 12,263,249 US 12,377,050 US 12,433,849 US 12,558,323 US 12,569,445 US 12,600,763